A phase 3 trial evaluating a nebulized clofazimine inhalation suspension (MNKD-101) for the treatment of refractory nontuberculous mycobacterial (NTM) lung disease has been discontinued. The ...
For most Americans, the letters "NTM" don’t mean anything. But for tens of thousands of people across the country, they represent something serious: a chronic lung disease that’s often overlooked, ...
BOSTON, June 27, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving ...
Highly effective modulator therapy is associated with declining NTM-PD rates in cystic fibrosis as well as improved NTM-PD outcomes in pwCF.
BRIDGEWATER, N.J., July 7, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, ...
Please provide your email address to receive an email when new articles are posted on . The ICoN-1 trial has been discontinued, and futility was the reason for this decision. The company is still ...
MIAMI, Aug. 4, 2025 /PRNewswire/ -- As the world prepares to observe World NTM Day on August 4, 2025, NTM Info & Research (NTMir) is calling on patients, physicians, caregivers, and policy leaders to ...
(Amy Leitman, JD, President of NTMir Contributor, USA Today) - For most Americans, the letters "NTM" don’t mean anything. But for tens of thousands of people across the country, they represent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results